Postmenopausal hormone therapy and atherosclerotic disease

https://doi.org/10.1016/0002-8703(94)90257-7Get rights and content

Abstract

Several lines of evidence suggest that estrogen is an important determinant of cardiovascular risk in women. Epidemiologic data document low rates of coronary heart disease (CHD) in premenopausal women, a narrowing of the gender gap in CHD mortality after menopause, and elevated risk of CHD among young women with bilateral oophorectomy not treated with estrogen. Nearly all of the more than 30 observational studies of exogenous estrogen replacement therapy have indicated a reduced risk of CHD among women receiving estrogen therapy. In a meta-analysis comparing estrogen users and nonusers, the estimated reduction of CHD among users was 44%. In angiographic studies, women taking estrogen were less likely to have coronary artery stenosis. Estrogen is known to affect a wide range of physiologic processes that may have an impact on CHD risk. Use of oral estrogen has favorable effects on serum lipid profiles; it increases high-density lipoprotein cholesterol levels by 10% to 15% and decreases low-density lipoprotein cholesterol levels by a similar magnitude. Other proposed mechanisms include inhibition of endothelial hyperplasia, reduced arterial impedance, enhanced production of prostacyclin, increased insulin sensitivity, and inhibition of oxidation of low-density lipoprotein. Nevertheless, the role of hormone replacement therapy in preventing clinical atherosclerotic events in women remains inconclusive because of the absence of randomized trial data. The benefit-to-risk ratio must be reliably assessed, because estrogen has complex actions, including postulated benefits (CHD, osteoporosis, and menopausal symptoms) and postulated risks (endometrial cancer, breast cancer, and gallstones). Furthermore, the addition of a progestin, which is commonly given to protect the endometrium, may attenuate the lipid benefits of estrogen; the benefit-to-risk ratio of such a combined regimen is even less certain. The Women's Health Initiative, a recently launched large-scale randomized trial of estrogen, estrogen-progestin, and placebo, as well as other ongoing randomized trials, will provide invaluable information to aid postmenopausal women in making the complex decision about whether to take hormone replacement therapy.

References (60)

  • J Haarbo et al.

    Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits

    J Clin Invest

    (1991)
  • J Potocki

    Wplyw leczenia estrogenami na niewydolnose wiencowa u kobiet po menopauzie

    Pol Tyg Lek

    (1971)
  • LE Nachtigall et al.

    Estrogen replacement therapy, II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems

    Obstet Gynecol

    (1979)
  • MJ Stampfer et al.

    A prospective study of postmenopausal estrogen therapy and coronary heart disease

    N Engl J Med

    (1985)
  • P Croft et al.

    Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraceptive study

    BMJ

    (1989)
  • ED Eaker et al.

    Coronary heart disease and its risk factors among women in the Framingham Study

  • MJ Stampfer et al.

    Menopause and heart disease: a review

    Ann NY Acad Sci

    (1990)
  • D Grady et al.

    Hormone therapy to prevent disease and prolong life in postmenopausal women

    Ann Intern Med

    (1992)
  • TL Bush et al.

    Effects of pharmacologic agents used, during menopause: impact on lipids and lipoproteins

  • VT Miller et al.

    Effects of conjugated equine estrogen with an without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1

    Obstet Gynecol

    (1991)
  • BW Walsh et al.

    Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins

    N Engl J Med

    (1991)
  • DJ Gordon et al.

    High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies

    Circulation

    (1989)
  • JE Manson et al.

    The primary prevention of myocardial infarction

    N Engl J Med

    (1992)
  • BB Sherwin et al.

    A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids

    Obstet Gynecol

    (1989)
  • WE Gibbons et al.

    Comparison of sequential versus continuous estrogen/progestin replacement therapy on serum lipid patterns: Multiuniversity National Upjohn Study Collaborative

    Society for Gynecologic Investigation

    (March 1991)
  • FM Sacks et al.

    The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice

    Ann NY Acad Sci

    (1990)
    FM Sacks et al.

    The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice

    Ann NY Acad Sci

    (1990)
  • AA Nabulsi et al.

    Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women

    N Engl J Med

    (1993)
  • EL Barrett-Connor et al.

    Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, Calif., revisited

    JAMA

    (1989)
  • E Farish et al.

    The effects of conjugated equine oestrogens with and without a cyclical progestin on lipoproteins and HDL subfractions in postmenopausal women

    Acta Endocrinol (Cophenhagen)

    (1986)
  • L Weinstein

    Efficacy of a continuous estrogen-progestin regimen in the menopausal patient

    Obstet Gynecol

    (1987)
  • Cited by (0)

    Supported by research grant No. HL 34594 from the National Institutes of Health.

    1

    Dr. Manson is a recipient of a Merck-Society for Epidemiologic Research Clinical Epidemiology Fellowship Award.

    View full text